Urokinase for Thrombolysis in Acute Ischemic Stroke

According to the Chinese Guidelines for the Diagnosis and Treatment of Ischemic Stroke, intravenous thrombolysis with urokinase, administered at doses of 1-1.5 million IU within 6 hours of symptom onset, has been shown to be both safe and effective for patients with acute ischemic stroke. Compared to alteplase, urokinase offers considerable cost advantages while maintaining comparable therapeutic efficacy. However, current dosing protocols in clinical practice largely rely on the empirical judgment of physicians rather than evidence-based standardization. Therefore, the development of a weight-adjusted dosing regimen for urokinase is of significant clinical importance in optimizing treatment outcomes and ensuring patient safety. The purpose of this study is to determine the maximum tolerated dose of urokinase thrombolytic treatment in patients with acute ischemic stroke and to develop an optimal weight-adjusted dosing regimen.

Inclusion Criteria: 1. Age 18-80 years, male or female. 2. Clinical diagnosis as ischemic stroke (the diagnosis following the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023). 3. Time from onset to treatment \1/3 of the middle cerebral artery). 2. Unknown time of stroke onset. 3. Pre-stroke mRS score ≥2. 4. NIHSS score 1A ≥2. 5. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.). 6. A history of intracranial hemorrhage. 7. Propensity for acute bleeding, including platelet count \1.7 or PT \>15s. 10. Patients with planned or prior endovascular therapy. 11. A history of severe head trauma or stroke within 3 months. 12. Intracranial tumors, large intracranial aneurysms. 13. A history of intracranial or spinal surgery within 3 months. 14. A history of major surgery within 2 weeks. 15. Severe liver impairment (e.g., liver failure, cirrhosis, portal hypertension \[esophageal varices\], active hepatitis). 16. A history of gastrointestinal or urinary tract hemorrhage within 3 weeks. 17. Active visceral bleeding. 18. Aortic dissection found. 19. A history of arterial puncture at sites difficult for compression hemostasis within 1 week. 20. Life expectancy \